M
Mary Johnston
Researcher at McMaster University
Publications - 19
Citations - 2624
Mary Johnston is an academic researcher from McMaster University. The author has contributed to research in topics: Cancer & Health care. The author has an hindex of 15, co-authored 19 publications receiving 2547 citations. Previous affiliations of Mary Johnston include Cancer Care Ontario.
Papers
More filters
Journal ArticleDOI
Effects of Computer-based Clinical Decision Support Systems on Clinician Performance and Patient Outcome: A Critical Appraisal of Research
TL;DR: This overview focuses on studies of the final and most clinically important stages of evaluation and examines controlled trials designed to measure the effects of CDSSs on clinician performance and patient outcomes.
Journal ArticleDOI
Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases
TL;DR: Meta-analysis of reported randomized trials shows no significant difference in complete and overall pain relief between single and multifraction palliative RT for bone metastases.
Journal ArticleDOI
Internists' Attitudes about Clinical Practice Guidelines
Sean R. Tunis,Robert Hayward,Mark C. Wilson,Haya R. Rubin,Eric B Bass,Mary Johnston,Earl P. Steinberg +6 more
TL;DR: A national survey of a random sample of American College of Physicians (ACP) members to assess ACP members' familiarity with, confidence in, and attitudes about guidelines issued by ACP and other organizations and members' perceptions of the effect of ACp and other guidelines on their practices.
Journal ArticleDOI
Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature.
G. Dranitsaris,Mary Johnston,Susan Poirier,T. Trudi Schueller,Debbie Milliken,Esther Green,Brent W. Zanke +6 more
TL;DR: A systematic review and meta-analysis conducted to test the hypothesis that oncology health care workers are at an increased risk of cancer, reproductive complications and acute toxic events identified a small incremental risk for spontaneous abortions in female staff working with cytotoxic agents.
Journal ArticleDOI
Systematic Review of First-Line Chemotherapy for Newly Diagnosed Postoperative Patients with Stage II, III, or IV Epithelial Ovarian Cancer
TL;DR: Intravenous carboplatin plus paclitaxel is the recommended postoperative chemotherapy regimen for newly diagnosed stage II-IV epithelial ovarian cancer and may also be considered a treatment option in patients for whom paclitxel is contraindicated or in patients who are unwilling to accept the adverse effects of pac litaxel chemotherapy.